Syndax Pharmaceuticals Inc’s recent filing unveils that its Chief Executive Officer Metzger Michael A unloaded Company’s shares for reported $2.58 million on Sep 08 ’25. In the deal valued at $16.41 per share,157,307 shares were sold. As a result of this transaction, Metzger Michael A now holds 298,661 shares worth roughly $4.58 million.
Then, MICHAEL METZGER bought 157,307 shares, generating $2,680,511 in total proceeds.
Before that, Podlesak Dennis sold 19,200 shares. Syndax Pharmaceuticals Inc shares valued at $304,170 were divested by the Director at a price of $15.84 per share. As a result of the transaction, Podlesak Dennis now holds 191,763 shares, worth roughly $2.94 million.
BTIG Research maintained its rating on August 05, 2025. It rated SNDX as “a Buy”.
Price Performance Review of SNDX
On Tuesday, Syndax Pharmaceuticals Inc [NASDAQ:SNDX] saw its stock jump 11.56% to $15.35. Over the last five days, the stock has gained 13.62%. Syndax Pharmaceuticals Inc shares have fallen nearly -18.61% since the year began. Nevertheless, the stocks have risen 16.11% over the past one year. While a 52-week high of $22.50 was reached on 08/28/25, a 52-week low of $8.58 was recorded on 05/15/25.
Levels Of Support And Resistance For SNDX Stock
The 24-hour chart illustrates a support level at 13.73, which if violated will result in even more drops to 12.12. On the upside, there is a resistance level at 16.38. A further resistance level may holdings at 17.42.
How much short interest is there in Syndax Pharmaceuticals Inc?
A steep rise in short interest was recorded in Syndax Pharmaceuticals Inc stocks on 2025-10-15, dropping by -1.12 million shares to a total of 22.02 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 23.14 million shares. There was a decline of -5.08%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on July 10, 2025 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $18 price target.
